- Revive Therapeutics (RVV) has announced a private placement for gross proceeds of between $3 million and $5 million
- The company will issue units priced at $0.15
- The offering is expected to close on or about December 14, 2022
- Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders
- Revive Therapeutics Ltd. (RVV) opened trading at C$0.175
Revive Therapeutics (RVV) has announced a private placement for gross proceeds of between $3 million and $5 million.
The company will issue units priced at $0.15. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share for a period of three years from the closing date of the offering.
The company will pay finder’s fees and issue finder warrants to EMD Financial Inc.
The offering is expected to close on or about December 14, 2022, and is subject to the receipt of all necessary regulatory approvals.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders.
Revive Therapeutics Ltd. (RVV) opened trading at C$0.175.
